LncRNA A2M-AS1 promotes ferroptosis in pancreatic cancer via interacting with PCBP3.
LncRNA A2M-AS1 promotes ferroptosis in pancreatic cancer via interacting with PCBP3.
复制标题
DOI:
10.1158/1541-7786.mcr-22-0024
复制
发表时间:
2022-08
期刊:
影响因子:
--
通讯作者:
X. Qiu;Qiuyue Shi;Xianglian Zhang;Xiaoyan Shi;Haixing Jiang;Shanyu Qin
中科院分区:
文献类型:
--
作者:
X. Qiu;Qiuyue Shi;Xianglian Zhang;Xiaoyan Shi;Haixing Jiang;Shanyu Qin
Ferroptosis is a newly-discovered cell death mechanism involved in the progression of various tumors, the role of non-coding RNAs (ncRNAs) in it was relatively less explored. This study identified the low levels of a recently studied long non-coding RNA (lncRNA), A2M-AS1, in pancreatic cancer (PC) and suggested its positive correlation with the overall survival time of PC patients. A2M-AS1 was mainly localized in the cytoplasm, inhibiting the cellular proliferation, migration, and invasion as well as the tumor growth of the PC cells. Moreover, the Erastin-induced ferroptosis increased the expression levels of A2M-AS1. The overexpression of A2M-AS1 promoted ferroptosis in the PC, which was inhibited by the silencing of A2M-AS1. Mechanically, A2M-AS1 could directly interact with the poly (rC) binding protein 3 (PCBP3), which plays an important role in the process of iron metabolism, thereby promoting the ferroptosis in PC. In addition, the A2M-AS1/PCBP3 axis could facilitate the p38 activation and inhibit the phosphorylation of the AKT-mTOR signaling pathway; all these participate in regulating ferroptosis. In conclusion, the regulation of ferroptosis by targeting the A2M-AS1/PCBP3 axis might provide a novel target for the treatment of PC in the future. Implications: A2M-AS1 might be a potential novel therapeutic target for PC patients in the future.